2008
DOI: 10.1093/brain/awn291
|View full text |Cite
|
Sign up to set email alerts
|

Abstract: Parkinson plus diseases, comprising mainly progressive supranuclear palsy (PSP) and multiple system atrophy (MSA) are rare neurodegenerative conditions. We designed a double-blind randomized placebo-controlled trial of riluzole as a potential disease-modifying agent in Parkinson plus disorders (NNIPPS: Neuroprotection and Natural History in Parkinson Plus Syndromes). We analysed the accuracy of our clinical diagnostic criteria, and studied prognostic factors for survival. Patients with an akinetic-rigid syndro… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

11
228
0
22

Year Published

2010
2010
2020
2020

Publication Types

Select...
5
3

Relationship

0
8

Authors

Journals

citations
Cited by 294 publications
(261 citation statements)
references
References 70 publications
11
228
0
22
Order By: Relevance
“…However, the differential diagnosis of parkinsonism continues to be challenging with a high misdiagnosis rate, particularly in the early stage [6], because parkinsonian patients show similar symptoms and specific symptoms do not appear in early stage [7]. It is of importance to make an accurate differential diagnosis of parkinsonism to decide on treatment regimens [8], provide a prognosis [9], investigate etiology and pathogenesis, and to develop new therapeutic strategies [10].…”
Section: Introductionmentioning
confidence: 99%
“…However, the differential diagnosis of parkinsonism continues to be challenging with a high misdiagnosis rate, particularly in the early stage [6], because parkinsonian patients show similar symptoms and specific symptoms do not appear in early stage [7]. It is of importance to make an accurate differential diagnosis of parkinsonism to decide on treatment regimens [8], provide a prognosis [9], investigate etiology and pathogenesis, and to develop new therapeutic strategies [10].…”
Section: Introductionmentioning
confidence: 99%
“…This drug did not have a significant effect on survival neither in the rate of functional deterioration 47 .…”
Section: Disease Modifying Therapiesmentioning
confidence: 73%
“…Die Ergebnisse dieser Studie ähneln denjenigen größerer Kohortenstudien in Europa [1,2]. Der Unterschied zu [1] ist, dass etablierte Kriterien für die MSA diagnostisch verwendet wurden.…”
Section: Etwas Neues?unclassified
“…Der Unterschied zu [1] ist, dass etablierte Kriterien für die MSA diagnostisch verwendet wurden. Bemerkenswert ist, dass die mittlere Überlebenszeit nach Einschluss nur 1,8 Jahre betrug.…”
Section: Etwas Neues?unclassified
See 1 more Smart Citation